For example, FCER2 was demonstrated to help predict response to ICS in multiple studies of children, yet there are no reports of the role of FCER2 in ICS response in adults.[11–13] Because the distribution, number, and type of genetic polymorphisms capable of predicting asthma treatment responses may vary with changes in asthma phenotypes resulting from age, understanding how age impacts pharmacogenetic traits is important for improving treatment outcomes for patients. The gene discussed is FCER2; the disease is asthma.